Nuclear Medicine Areas
The division provides a wide spectrum of nuclear medicine procedures:
Brain
- DaTSCAN for differentiating Parkinsons from other movement disorders
- PET FDG and amyloid plaque imaging for dementia
- PET / MRI fusion imaging for tumor and seizure evaluation
- Custom PET radiopharmaceuticals for research in neurologic and psychiatric studies (C-11 DASB, C-11 Raclopride, C-11 DAA1106, F-DOPA)
Endocrine
- Thyroid uptake and scans
- Thyroid cancer imaging (I-131 and I-123) and therapy with radioiodine
- SPECT pentaoctreotide and PET dotatate imaging for neuroendocrine tumors
- Parathyroid imaging with SPECT/CT
- MIBG imaging for pheochromocytoma and neuroblastoma
Cardiovascular
- Myocardial perfusion imaging with SPECT/CT
- Myocardial viability imaging with SPECT and PET
- MUGA and First pass imaging
- Cardiac shunt evaluation
- Myocardial MIBG imaging for sympathetic innervation
- Myocardial pyrophosphate imaging for detection of amyloidosis
Pulmonary
- V/Q imaging, planar and SPECT, for acute and chronic thromboembolic disease
- Quantitative V/Q imaging for pre-surgical evaluation
Gastroenterology
- emptying and gastroesophageal reflux studies
- HIDA scans for hepatobiliary function, gallbladder function, sphincter of Oddi, biliary atresia, and biliary leak
- SPECT imaging for hemangiomas and focal nodular hyperplasia
- Salivary gland imaging
- Meckel's scan for detection of gastrointestinal mucosa
- Acute GI bleeding scan
- Peritoneal-venous shunt patency (LeVeen, Denver shunts)
Genitourinary Imaging
- Renal imaging for differential function, hydronephrosis, renovascular hypertension
- Quantitative measurement of glomerular filtration rate (GFR)
- Ureteral reflux study
- Bladder residual volume measurement
- Testicular flow imaging
Oncology
- PET/CT tumor imaging with 18F-fluoro-2-deoxyglucose (FDG)
- PET/CT bone metastases imaging with 18F-NaF
- PET/CT imaging with 18F-fluciclovine (Axumin) in prostate cancer
- PET/CT research with custom PET radiopharmaceuticals (e.g. FLT)
- SPECT/CT imaging with standard clinical and research radiopharmaceuticals
- Ra-223 therapy for prostate cancer and research in other cancers
- Research with new radiopharmaceutical therapies (e.g. Lu-177)
- Development of new radiopharmaceuticals and applications in tumor and lymph node imaging (e.g. Lymphoseek, FDA approved 3/13/13)